Hazard Score Can Estimate Age of Prostate Cancer Diagnosis
THURSDAY, Jan. 11, 2018 -- A hazard score calculated from 54 single nucleotide polymorphisms can predict age at diagnosis of aggressive prostate cancer (PCa), according to a study published online Jan. 10 in The BMJ.
Tyler M. Seibert, M.D., from the University of California, San Diego, in La Jolla, and colleagues developed and validated a genetic tool to predict age of onset of aggressive PCa. Single nucleotide polymorphisms associated with diagnosis were selected in analysis of genotype, PCa status, and age. To estimate their effects on age at diagnosis of aggressive PCa, these polymorphisms were incorporated into a survival analysis. The development and validation datasets comprised 31,747 and 6,411 men, respectively.
The researchers found that the hazard score calculated from 54 single nucleotide polymorphisms significantly predicted age at diagnosis of aggressive cancer in the independent validation set. The hazard ratio for aggressive cancer was 2.9 when comparing men in the validation set with high scores (>98th centile) to those with average scores (30 to 70th centile). Prediction of onset of aggressive PCa was not improved by inclusion of family history in a combined model; when family history was accounted for, polygenic hazard score performance remained high. With increasing polygenic hazard score, the positive predictive value of prostate-specific antigen screening for aggressive PCa was increased.
"Polygenic hazard scores can be used for personalized genetic risk estimates that can predict for age at onset of aggressive PCa," the authors write.
Several authors disclosed financial ties to the pharmaceutical and medical technology industries.
© 2020 HealthDay. All rights reserved.
Posted: January 2018
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
- Monthly Update Archive
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.